Nektar Therapeutics (NQ:NKTR)
Delayed: 9.27 -0.04 (0.43%)
Trade Now!
Previous Close $9.31    52 Week High $11.34 
Open $9.30    52 Week Low $5.65 
Day High $9.50    P/E N/A 
Day Low $9.11    EPS $-1.62 
Volume 305       

Friends, Peers and Foes (?): AZN, BAYN, BAYRY, THRX, CBST (more...)

May 21, 2013 09:25 AM Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013
May 16, 2013 06:02 PM Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
May 9, 2013 04:51 PM Form 8-K NEKTAR THERAPEUTICS For: May 09
May 9, 2013 04:46 PM Form 10-Q NEKTAR THERAPEUTICS For: Mar 31
May 9, 2013 04:22 PM Nektar Therapeutics (NKTR) Misses Q1 EPS by 6c, Sales Rise
May 9, 2013 04:15 PM Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
May 2, 2013 05:00 PM Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
Apr 16, 2013 05:00 AM Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
Apr 7, 2013 01:00 PM Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
Mar 20, 2013 10:41 AM MKM Partners Reiterates Bullish Stance on Nektar Therapeutics (NKTR); Phase 3 to Start this Month
View All Articles

Entities mentioned with NKTR

View All Entities